Spots Global Cancer Trial Database for Phase 1 Study of PLX7486 as Single Agent in Patients With Advanced Solid Tumors

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Phase 1 Study of PLX7486 as Single Agent in Patients With Advanced Solid Tumors

Official Title: A Phase 1 Study to Assess Safety, Pharmacokinetics, and Pharmacodynamics of PLX7486 as a Single Agent in Patients With Advanced Solid Tumors

Study ID: NCT01804530

Conditions

Solid Tumor

Tumors of Any Histology With Activating Trk (NTRK) Point or NTRK Fusion Mutations

Tenosynovial Giant Cell Tumor

Interventions

PLX7486 TsOH

Study Description

Brief Summary: The objective of this study is to determine the safety, pharmacokinetics, maximum tolerated dose/recommended Phase 2 dose, and efficacy of PLX7486.

Detailed Description: Part 1. Open-label, sequential PLX7486 TsOH single-agent dose escalation in approximately 60 patients with solid tumors.